This is a long-duration catalyst with first interim readouts not expected until late 2027 at the earliest. Traders should watch for enrollment updates and interim data readouts as nearer-term catalysts, but avoid chasing the initial headline given the extended timeline and weak historical price action.
Price Chart
Executive Summary
Optimi Health announced a Health Canada-authorized Phase 2 clinical trial evaluating psilocybin-assisted therapy for major depressive disorder, enrolling up to 200 participants with dosing expected by end of 2027. The company will supply its own GMP-manufactured psilocybin and retains exclusive ownership of trial results, marking its largest clinical commitment to date.
Key Facts
- Optimi Health announced a Phase 2 clinical trial for psilocybin-assisted therapy in major depressive disorder (MDD), authorized by Health Canada.
- Trial will enroll up to 200 participants across multiple Canadian sites, with dosing expected to be completed by end of 2027.
- Optimi will supply its own naturally derived psilocybin from its GMP facility and retain exclusive ownership of trial results.
- CEO stated the trial can be 'comfortably funded with current cash on hand.'
- The company holds a Drug Establishment Licence and currently supplies psilocybin through Health Canada's Special Access Program.
Financial Impact
No financial figures reported; CEO stated the trial can be funded with current cash on hand.
Risk Factors
- Trial results are years away (dosing completion end of 2027) with no interim data timeline provided.
- Psilocybin-assisted therapy has not received market authorization from Health Canada; regulatory path remains uncertain.
- Small market cap ($25M) and low institutional ownership create high volatility risk.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-005973 |
| Document: f6k_091026.htm | 0001171843-26-005973 |
| Document: 0001171843-26-005973-index-headers.html | 0001171843-26-005973 |
| Document: 0001171843-26-005973-index.html | 0001171843-26-005973 |
| Document: 0001171843-26-005973.txt | 0001171843-26-005973 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 6-K | $3.36 | awaiting T+5 | — | $3.12 (−7.14%) |
Oct 20, 2026 6d ago | 6-K | $3.36 | awaiting T+5 | — | $3.12 (−7.14%) |
Oct 7, 2026 19d ago | 6-K | $4.04 $3.17 | ▼ −21.66% | ▼ −20.68% | $3.12 (−22.77%) |
Oct 5, 2026 21d ago | SC 13G/A | $4.13 $3.50 | ▼ −15.25% | ▼ −15.12% | $3.12 (−24.46%) |
Sep 29, 2026 27d ago | 6-K | $4.78 $4.13 | ▼ −13.60% | ▼ −15.55% | $3.12 (−34.73%) |
Sep 23, 2026 4w ago | 6-K | $4.96 $4.71 | ▼ −5.04% | ▼ −4.37% | $3.12 (−37.10%) |
Sep 22, 2026 4w ago | 6-K | $4.96 $4.78 | ▼ −3.63% | ▼ −2.44% | $3.12 (−37.10%) |
Sep 16, 2026 5w ago | 6-K | $4.90 $4.96 | ▲ +1.22% | ▼ −0.60% | $3.12 (−36.33%) |
Sep 10, 2026 6w ago | 6-K | $4.50 $4.96 | ▲ +10.22% | ▲ +10.72% | $3.12 (−30.67%) |
Aug 26, 2026 8w ago | 6-K | $4.89 $4.70 | ▲ +3.89% | ▲ +4.15% | $3.12 (+36.20%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers